Karthik Suresh, MD | Authors

Palos Heights



Pneumonitis From Anti–PD-1/ PD-L1 Therapy

October 15, 2017

While the incidence of irAEs is relatively low, the absolute number of patients receiving immune checkpoint inhibitors is steadily increasing. Thus, it is likely that, with time, larger numbers of patients will develop irAEs, including pneumonitis.